Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer

INTRODUCTION: Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Koji, Muraoka, Kei, Fukasawa, Michiko, Fukushima, Mika, Kumagai, Masatoshi, Yabusaki, Ryo, Ueda, Masakatsu, Shiraishi, Yusuke, Imamura, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249652/
https://www.ncbi.nlm.nih.gov/pubmed/35795109
http://dx.doi.org/10.1002/iju5.12457
_version_ 1784739633060380672
author Yoshimura, Koji
Muraoka, Kei
Fukasawa, Michiko
Fukushima, Mika
Kumagai, Masatoshi
Yabusaki, Ryo
Ueda, Masakatsu
Shiraishi, Yusuke
Imamura, Masaaki
author_facet Yoshimura, Koji
Muraoka, Kei
Fukasawa, Michiko
Fukushima, Mika
Kumagai, Masatoshi
Yabusaki, Ryo
Ueda, Masakatsu
Shiraishi, Yusuke
Imamura, Masaaki
author_sort Yoshimura, Koji
collection PubMed
description INTRODUCTION: Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a long period. CASE PRESENTATION: We treated a patient with super‐high‐risk, nonmetastatic prostate cancer, with triple combination therapy. He was biochemical relapse free at 60 months after the initiation of treatment. CONCLUSION: Triple combination therapy may be an option for super‐high‐risk, nonmetastatic prostate cancer.
format Online
Article
Text
id pubmed-9249652
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92496522022-07-05 Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer Yoshimura, Koji Muraoka, Kei Fukasawa, Michiko Fukushima, Mika Kumagai, Masatoshi Yabusaki, Ryo Ueda, Masakatsu Shiraishi, Yusuke Imamura, Masaaki IJU Case Rep Case Reports INTRODUCTION: Patients with nonmetastatic but exceptionally high‐risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen‐deprivation therapy, as first‐line treatment, may control the disease for a long period. CASE PRESENTATION: We treated a patient with super‐high‐risk, nonmetastatic prostate cancer, with triple combination therapy. He was biochemical relapse free at 60 months after the initiation of treatment. CONCLUSION: Triple combination therapy may be an option for super‐high‐risk, nonmetastatic prostate cancer. John Wiley and Sons Inc. 2022-05-13 /pmc/articles/PMC9249652/ /pubmed/35795109 http://dx.doi.org/10.1002/iju5.12457 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Yoshimura, Koji
Muraoka, Kei
Fukasawa, Michiko
Fukushima, Mika
Kumagai, Masatoshi
Yabusaki, Ryo
Ueda, Masakatsu
Shiraishi, Yusuke
Imamura, Masaaki
Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title_full Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title_fullStr Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title_full_unstemmed Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title_short Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
title_sort triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249652/
https://www.ncbi.nlm.nih.gov/pubmed/35795109
http://dx.doi.org/10.1002/iju5.12457
work_keys_str_mv AT yoshimurakoji triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT muraokakei triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT fukasawamichiko triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT fukushimamika triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT kumagaimasatoshi triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT yabusakiryo triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT uedamasakatsu triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT shiraishiyusuke triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer
AT imamuramasaaki triplecombinationtherapyforclinicallynonmetastaticsuperhighriskprostatecancer

Ejemplares similares